Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Receptor, ErbB-2

abstract

  • rhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy. This is evidence that targeting growth factor receptors can cause regression of human cancer and justifies further evaluation of this agent.

publication date

  • March 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8622019

Additional Document Info

start page

  • 737

end page

  • 44

volume

  • 14

number

  • 3